129-20-4
中文名称
羟保松
英文名称
OXYPHENYL BUTAZONE
CAS
129-20-4
EINECS 编号
204-936-2
分子式
C19H20N2O3
MDL 编号
MFCD00057278
分子量
324.37
MOL 文件
129-20-4.mol
129-20-4 结构式
基本信息
中文别名
羟保松羟布宗
羟基保泰松
羟基保泰松,坦特利尔,羟保松
英文别名
LABOTEST-BB LT00134684OXYPHENYL BUTAZONE
1-(p-Hydroxyphenyl)-2-phenyl-3,5-dioxo-4-N-butylpyrazolidine
1-(p-Hydroxyphenyl)-2-phenyl-4-butyl-3,5-pyrazolidinedione
1-(p-hydroxyphenyl)-2-phenyl-4-butylpyrazolidine-3,5-dione
1-Phenyl-2-(p-hydroxyphenyl)-3,5-dioxo-4-butylpyrazolidine
1-phenyl-2-(p-hydroxyphenyl)-3,5-dioxo-4-n-butylpyrazolidine
1-p-hydroxyphenyl-2-phenyl-3,5-dioxo-4-n-butylpyrazolidine
3,5-Dioxo-1-phenyl-2-(p-hydroxyphenyl)-4-N-butylpyrazolidene
3,5-Pyrazolidinedione, 4-butyl-1-(4-hydroxyphenyl)-2-phenyl-
3,5-Pyrazolidinedione, 4-butyl-1-(p-hydroxyphenyl)-2-phenyl-
3,5-pyrazolidinedione,4-butyl-1-(4-hydroxyphenyl)-2-phenyl
4-Butyl-1-(4-hydroxyphenyl)-2-phenyl-3,5-pyrazolidinedione
4-Butyl-1-(p-hydroxyphenyl)-2-phenyl-3,5-pyrazolidinedione
4-butyl-1-(p-hydroxyphenyl)-2-phenyl-5-pyrazolidinedione
4-Butyl-2-(4-hydroxyphenyl)-1-phenyl-3,5-dioxopyrazolidine
4-Butyl-2-(p-hydroxyphenyl)-1-phenyl-3,5-pyrazolidinedione
Artroflog
BM 1
bm1
所属类别
原料药：非甾抗炎药物理化学性质
外观性状白色结晶或结晶性粉末。熔点124-125℃。易溶于乙醇、丙酮，溶于氯仿、苯、醚，不溶于水。易溶于氢氧化碳或碳酸碱溶液。无臭，味苦。
熔点109-111°C
沸点462.71°C (rough estimate)
密度1.2118 (rough estimate)
折射率1.6140 (estimate)
储存条件-20°C
溶解度DMSO：可溶10mg/mL，澄清
酸度系数(pKa)pKa 4.7/10.0±0.2(H2O,t =25,Iundefined) (Uncertain)
形态粉末
颜色白色至棕色
水溶解性20mg/L(room temperature)
稳定性吸湿性
(IARC)致癌物分类3 (Vol. 13, Sup 7) 1987
常见问题列表
生物活性
Oxyphenbutazone 是一种苯丁酮衍生物，具有抗炎作用。Oxyphenbutazone 是一种非选择性的 COX 抑制剂。Oxyphenbutazone 能选择性地杀死不复制的结核分枝杆菌。靶点
COX
体外研究
Oxyphenbutazone enhances the anticancer efficiency of methotrexate (MTX) in Hep3B cells.
Oxyphenbutazone (2.5 -7.5 µM; 48 hours) co-treatment with (MTX, 0.25-1.0 µM) shows potential cytotoxicity against Hep3B cells.
Oxyphenbutazone exhibits reparative effects in the hepatocytes.
Cell Cytotoxicity Assay
| Cell Line: | Hep3B cells |
| Concentration: | 2.5 µM, 5 µM, 7.5 µM |
| Incubation Time: | 48 hours |
| Result: | Enhanced the cytotoxicity of MTX. |
体内研究
Oxyphenbutazone (70 mg/kg/week; p.o.; in two divided doses; for 13 weeks) exerts potential anticancer activity when co-treatment with MTX (5.0 or 2.5 mg/kg/week; i.p.).
| Animal Model: | 5–6 weeks Wistar strain albino male rats (150–220 g) |
| Dosage: | 70 mg/kg/week (co-treatment with MTX 5.0 or 2.5 mg/kg/week) |
| Administration: | Oral administration; once a week; in two divided doses; for 13 weeks |
| Result: | Exerted potential anticancer activity in rats when co-treatment with MTX. |